Tick tock; slow the eGFR clock: managing kidney risk in people with T2D
Seminar
•
AstraZeneca
About the CPD course
A thorough presentation developed for UK based healthcare professionals, detailing the impact of declining eGFR on patients and mortality risk, and the impact of early intervention. This deck also contextualises the outcomes of landmark clinical trials, and highlights the impact of dapagliflozin treatment on a hypothetical patient profile.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines.
Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive, open and collaborative. This approach runs through all that we do.